677 Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal cancer

• Tc Wu,
• Francis Worden,
• Michael K Gibson,
• Panayiotis Savvides,
• Ellen Heimann-Nichols,
• Richard Roden,
• Yung-Nien Chang

Affiliations

Tc Wu

Aff4 grid.21107.350000000121719311Obstetrics and GynecologyJohns Hopkins Medical Institutions Baltimore MD USA

Francis Worden

12University of Michigan Health System Comprehensive, Ann Arbor, MI, USA

Michael K Gibson

6Vanderbilt University Medical Center, Nashville, TN, USA

Panayiotis Savvides

2Mayo Clinic, Scottsdale, AZ, USA

Ellen Heimann-Nichols

1Vanderbilt University Medical Center, Nashville, TN, USA

Richard Roden

4Johns Hopkins University, Baltimore, MD, USA

Yung-Nien Chang

5PapiVax Biotech, Inc., Taipei, Taipei, Taiwan